Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

MLA

Yoshiyuki Onda, et al. “Real-World Effectiveness and Safety Analysis of Carfilzomib–lenalidomide–dexamethasone and Carfilzomib–dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Analysis.” Therapeutic Advances in Hematology, vol. 13, June 2022. EBSCOhost, https://doi.org/10.1177/20406207221104584.

APA

Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, … Junya Kuroda. (2022). Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Therapeutic Advances in Hematology, 13. https://doi.org/10.1177/20406207221104584

Chicago

Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, et al. 2022. “Real-World Effectiveness and Safety Analysis of Carfilzomib–lenalidomide–dexamethasone and Carfilzomib–dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Analysis.” Therapeutic Advances in Hematology 13 (June). doi:10.1177/20406207221104584.